ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / INBS / news
TNON (30) SNOA (34) NVNO (33) WOK (51) ⌘ Pro Terminal →

Why INBS Stock dropped -5.68% Today — RQD Quant Desk Flash

$1.66 -5.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.64

Intelligent Bio Solutions Inc. (INBS) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INBS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INBS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Intelligent Bio Solutions Inc. (NASDAQ: INBS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.66 (-5.68% 1D, market cap $5.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, INBS ranks #892 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INBS compare to TNON and SNOA in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), INBS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 40.8%, and ROIC of -35.0%. By comparison, TNON (Tenon Medical Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, INBS leads on earnings multiple (N/A) while INBS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INBS?
▼

Per INBS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001725430), Intelligent Bio Solutions Inc. generated $3.1M in revenue (-1.9% YoY), -$10.6M in net income, and -$9.9M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.64 (-1.21%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510027
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (7)Whales (5)SEC (5)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.9% Base Target
$26 Bull$1 Base$1 Bear
📬 FREE INBS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INBS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY INBS SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+7/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 40.8% Gross Margin

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 52.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
19
Grade E$1.48+12.8% Next Q
Q2 (-2Q)
22
Grade E$1.67+3% Next Q
Q3 (-1Q)
24
Grade E$1.72-3.5% Next Q
Current
27
Grade E$1.66-10.3% Hist 90D α
Trajectory: E (19) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INBS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INBS currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.85) and Max Pain ($1.74) forces dealer call-delta covering toward $26.14.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INBS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INBS Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why INBS Stock dropped -5.68% Today — RQD Quant Desk Flash

Intelligent Bio Solutions Inc. (INBS) dropped -5.68% to $1.66, trading at 2% of its 52-week range ($1.35 – $24.9). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($1.35 – $24.9) with RSI-14 at 52.5 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.66 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 40.8% gross margin and $0 annual free cash flow.
Live INBS Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INBS)

  • ✓Walkthrough of INBS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
INBS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.60%⚡ TESTING RESISTANCE
2026-11-03O $1.83H $1.83L $1.66C $1.66VOL 18.2K
RES: $1.83SUP: $1.02SMA50: $1.85SMA200: $3.05
$9.61$7.37$5.13$2.89$0.66RES $1.83SUP $1.02$1.662026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INBS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INBS Butterfly Map → + Track INBS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -1.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INBS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INBS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INBS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INBS)

Health Care Rank #892 of 1015 ⚔️ TNON vs INBS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INBS vs. TNON, SNOA, NVNO, WOK)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Intelligent Bio Solutions Inc. (INBS) ranks #892 by composite RQD confidence (27/100, grade E) and #928 by equity capitalization ($5.8M). Within this direct 5-issuer industry benchmark cohort, INBS leads on earnings valuation at N/A trailing P/E, while INBS leads on capital efficiency and profitability with -35.0% ROIC and 40.8% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with INBS at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INBS ACTIVE
Intelligent Bio Solutions Inc.
E 27/100 — 40.8% -35.0% -5.68% $5.8M Benchmark Subject
TNON
Tenon Medical Inc.
E 30/100 — 59.8% -35.0% -5.85% $5.5M /tnon-vs-inbs →
SNOA
Sonoma Pharmaceuticals Inc.
E 34/100 — 38.0% -35.0% 0.00% $5.3M /snoa-vs-inbs →
NVNO
enVVeno Medical Corporation
E 33/100 — — -35.0% +2.08% $4.7M /nvno-vs-inbs →
WOK
WORK Medical Technology Group LTD (Class A)
D 51/100 — — — 0.00% $4.5M /wok-vs-inbs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001725430 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Intelligent Bio Solutions Inc. (INBS) reported GAAP revenue of $3.1M (-1.9% vs. FY2024 revenue of $3.1M , and +142.9% cumulative change since FY2023) , GAAP net income of -$10.6M, operating cash flow of -$9.7M, and free cash flow of -$9.9M (-1.2% YoY). On the balance sheet, INBS closed FY2025 with $17.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $3.1M -$10.6M -$9.7M -$9.9M $17.7M —
FY2024 (FY) 2024-06-30 $3.1M -$10.2M -$9.6M -$9.8M $8.7M —
FY2023 (FY) 2023-06-30 $1.3M -$10.6M -$7.4M -$7.4M — —

3. INBS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INBS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Intelligent Bio Solutions Inc. (NASDAQ: INBS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.66 (-5.68% 1D, market cap $5.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, INBS ranks #892 in composite RQD confidence.

How does INBS compare to TNON and SNOA in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), INBS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 40.8%, and ROIC of -35.0%. By comparison, TNON (Tenon Medical Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, INBS leads on earnings multiple (N/A) while INBS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INBS?

Per INBS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001725430), Intelligent Bio Solutions Inc. generated $3.1M in revenue (-1.9% YoY), -$10.6M in net income, and -$9.9M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INBS trading relative to its 50-day, 200-day, and 52-week technical levels?

INBS last traded at $1.66 (-5.68% on volume of 26,489 shares), positioning the stock -10.27% below its 50-day simple moving average ($1.85) and -45.57% below its 200-day simple moving average ($3.05). Across its 52-week range of $1.35 to $24.90, INBS sits at the 1.3% percentile with a 14-day RSI of 52.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.45 to $1.87).

Direct Sub-Reports: INBS RQD Cockpit INBS 12M Forecast INBS Earnings & Move INBS Dividends & DRIP INBS Insiders & 13F INBS Whale Options INBS Profit Sankey INBS News & Why
ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ SEC XBRL & RQD VERIFIED

INBS — Intelligent Bio Solutions Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Intelligent Bio Solutions Inc. (INBS) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.66 (-5.68% 1D, market capitalization $5.8M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 40.8%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Intelligent Bio Solutions Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. It is classified under these sector and industry designations.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Intelligent Bio Solutions Inc. (INBS) reported $3.1M in annual revenue (up from $3.1M in FY2024, -1.9% YoY) and -$10.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.3M revenue, -$10.6M net income) through FY2025, INBS scaled operating cash flow to -$9.7M and free cash flow to -$9.9M, backed by $17.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $1.35 – $24.90 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be mapped from the source. Sector-level context is limited to Health Care / Medical/Dental Instruments. Second-order bottlenecks cannot be identified from the provided data.

  • Key Question #1: Can INBS sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.1M and free cash flow of -$9.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is INBS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

INBS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Intelligent Bio Solutions Inc. (INBS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INBS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INBS Bull vs. Bear Conversation Board — What's Your Call at $1.66?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INBS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on INBS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $2.02 (+14.8%)
📌 Pinned Debate

The stock trades at a $6.1M market cap with revenue of $3.1M, leaving room for a sharp re-rating if operating losses narrow.

The stock trades at a $6.1M market cap with revenue of $3.1M, leaving room for a sharp re-rating if operating losses narrow.. When you look under the hood at INBS, Fundamental Cash Engine is 7/20 with 40.8% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $24.90. My 12M target is $2.02.

EarningsSniper 🐂 BULL

Both sides have a point here — INBS's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.36 (-22.7%)
Spot @ $1.76

Operating margin of -60%, FCF of -$9.9M against $0.7M in cash, and a Piotroski F-Score of 3/9 point to acute funding and forensic risk.

Operating margin of -60%, FCF of -$9.9M against $0.7M in cash, and a Piotroski F-Score of 3/9 point to acute funding and forensic risk.. Look at the math on INBS: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $1.55 before getting long.

LIVE TAPE